[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610498":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":42,"locations":48,"responsibleParty":183,"collaborators":29,"id":185,"slug":29,"hasResults":186,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":186,"sex":192,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":29,"studyType":198,"phases":199,"briefSummary":201,"conditions":202,"keywords":29,"overallStatus":72,"whyStopped":29,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A - Cohort A1","EXPERIMENTAL","Participants will receive 4 doses of AZD1613 or placebo on days 1, 29, 57 and 85.",[13,14],"Drug: AZD1613 - Part A","Drug: Placebo - Part A",{"label":16,"type":10,"description":11,"interventionNames":17},"Part A - Cohort A2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Part B - Chinese Cohort",[13,21,22],"Drug: AZD1613 - Part B","Drug: Placebo - Part B",[24,30,34,38],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","AZD1613 - Part A","Part A - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.",[9,16,19],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Placebo - Part A","Part A - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.",[9,16],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"AZD1613 - Part B","Part B - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.",[19],{"type":25,"name":39,"description":40,"armGroupLabels":41,"otherNames":29},"Placebo - Part B","Part B - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.",[19],[43],{"name":44,"role":45,"phone":46,"phoneExt":29,"email":47},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[49,62,71,81,89,98,107,116,125,134,142,150,158,166,174],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":29},"Research Site","NOT_YET_RECRUITING","Birmingham","Alabama","35233","United States",{"type":57,"coordinates":58},"Point",[59,60],-86.80249,33.52066,{"lat":60,"lon":59},{"facility":50,"status":51,"city":63,"state":64,"zip":65,"country":55,"cosmosGeoPoint":66,"geoPoint":70,"contacts":29},"Loma Linda","California","92354",{"type":57,"coordinates":67},[68,69],-117.26115,34.04835,{"lat":69,"lon":68},{"facility":50,"status":72,"city":73,"state":74,"zip":75,"country":55,"cosmosGeoPoint":76,"geoPoint":80,"contacts":29},"RECRUITING","Jacksonville","Florida","32216",{"type":57,"coordinates":77},[78,79],-81.65565,30.33218,{"lat":79,"lon":78},{"facility":50,"status":72,"city":82,"state":74,"zip":83,"country":55,"cosmosGeoPoint":84,"geoPoint":88,"contacts":29},"Orlando","32808",{"type":57,"coordinates":85},[86,87],-81.37924,28.53834,{"lat":87,"lon":86},{"facility":50,"status":72,"city":90,"state":91,"zip":92,"country":55,"cosmosGeoPoint":93,"geoPoint":97,"contacts":29},"Lenexa","Kansas","66219",{"type":57,"coordinates":94},[95,96],-94.73357,38.95362,{"lat":96,"lon":95},{"facility":50,"status":51,"city":99,"state":100,"zip":101,"country":55,"cosmosGeoPoint":102,"geoPoint":106,"contacts":29},"Baltimore","Maryland","21201",{"type":57,"coordinates":103},[104,105],-76.61219,39.29038,{"lat":105,"lon":104},{"facility":50,"status":72,"city":108,"state":109,"zip":110,"country":55,"cosmosGeoPoint":111,"geoPoint":115,"contacts":29},"Rochester","Minnesota","55905",{"type":57,"coordinates":112},[113,114],-92.4699,44.02163,{"lat":114,"lon":113},{"facility":50,"status":51,"city":117,"state":118,"zip":119,"country":55,"cosmosGeoPoint":120,"geoPoint":124,"contacts":29},"San Antonio","Texas","78212",{"type":57,"coordinates":121},[122,123],-98.49363,29.42412,{"lat":123,"lon":122},{"facility":50,"status":51,"city":126,"state":29,"zip":127,"country":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":29},"Chengdu","610072","China",{"type":57,"coordinates":130},[131,132],104.06667,30.66667,{"lat":132,"lon":131},{"facility":50,"status":51,"city":135,"state":29,"zip":136,"country":128,"cosmosGeoPoint":137,"geoPoint":141,"contacts":29},"Hangzhou","310003",{"type":57,"coordinates":138},[139,140],120.16142,30.29365,{"lat":140,"lon":139},{"facility":50,"status":51,"city":143,"state":29,"zip":144,"country":128,"cosmosGeoPoint":145,"geoPoint":149,"contacts":29},"Nanjing","210009",{"type":57,"coordinates":146},[147,148],118.77778,32.06167,{"lat":148,"lon":147},{"facility":50,"status":51,"city":151,"state":29,"zip":152,"country":128,"cosmosGeoPoint":153,"geoPoint":157,"contacts":29},"Shanghai","200025",{"type":57,"coordinates":154},[155,156],121.45806,31.22222,{"lat":156,"lon":155},{"facility":50,"status":51,"city":159,"state":29,"zip":160,"country":128,"cosmosGeoPoint":161,"geoPoint":165,"contacts":29},"Wuhan","430022",{"type":57,"coordinates":162},[163,164],114.26667,30.58333,{"lat":164,"lon":163},{"facility":50,"status":51,"city":167,"state":29,"zip":168,"country":128,"cosmosGeoPoint":169,"geoPoint":173,"contacts":29},"Xiamen","361101",{"type":57,"coordinates":170},[171,172],118.08187,24.47979,{"lat":172,"lon":171},{"facility":50,"status":72,"city":175,"state":29,"zip":176,"country":177,"cosmosGeoPoint":178,"geoPoint":182,"contacts":29},"London","NW3 2QG","United Kingdom",{"type":57,"coordinates":179},[180,181],-0.12574,51.50853,{"lat":181,"lon":180},{"type":184,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100610498",false,"NCT07228364","Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease","A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease","PIONEER-PKD","Inclusion Criteria:\n\n* Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes\n* eGFR = 45 to 90 mL\u002Fmin \u002F1.73m2\n* Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg\u002Fm2 (inclusive).\n* Females are to be of non-childbearing potential\n\nExclusion Criteria:\n\n* As judged by the investigator, any evidence of cardiac, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the participant to participate in the study.\n* Positive hepatitis C antibody, hepatitis B virus surface antigen, or human immunodeficiency virus test, at screening.\n* History of QT prolongation associated with other medications that required discontinuation of that medication.\n* Congenital long QT syndrome.\n* History of ventricular arrhythmia requiring treatment. Patients with atrial fibrillation\u002Fflutter and controlled ventricular rate HR \\\u003C 100 bpm can be eligible as judged by the investigator.\n* Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.\n* Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.\n* Systolic BP \\> 160 mmHg or diastolic BP \\> 100mmHg or HR \\\u003C 50 bpm or \\> 100 bpm at screening. Patients taking anti-hypertensive medication should be on a stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.\n* Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period.","ALL","18 Years","65 Years",{"count":196,"type":197},40,"ESTIMATED","INTERVENTIONAL",[200],"PHASE1","A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).",[203],"Autosomal Dominant Polycystic Kidney Disease","2026-05-08",{"date":206,"type":207},"2026-05-11","ACTUAL",{"date":209,"type":207},"2025-11-10",{"date":211,"type":197},"2027-01-26",{"name":5,"class":6},15]